Perspective
Volume 12:04, 2024

Journal of Cardiovascular Diseases & Diagnosis

ISSN: 2329-9517 Open Access

Novel Biomarkers for Early Detection of Cardiovascular Disease

Stefani Karan*

Department of Vascular Surgery, Aix Marseille University, Marseille, France

Introduction

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide. Early detection is crucial for effective management and improved patient outcomes. Traditional biomarkers like cholesterol and blood pressure have been used for decades, but they have limitations in predicting disease onset. Recent advancements in molecular biology and genomics have led to the discovery of novel biomarkers that offer more precise and earlier detection of CVD. This article explores these emerging biomarkers, including genetic markers, epigenetic factors, and protein-based indicators, highlighting their potential to revolutionize cardiovascular risk assessment and preventive strategies. Cardiovascular disease encompasses a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. Early detection and intervention are key to reducing the burden of CVD, but current diagnostic tools often fall short in identifying individuals at risk before symptoms develop. Traditional biomarkers like Low-Density Lipoprotein (LDL) cholesterol, High-Density Lipoprotein (HDL) cholesterol, and blood pressure are widely used but have limitations in sensitivity and specificity. As a result, there is a growing interest in identifying novel biomarkers that can detect CVD at an earlier stage, potentially even before clinical symptoms manifest [1].

Description

Genetic predisposition plays a significant role in the development of cardiovascular disease. Advances in genomics have enabled the identification of specific genetic variants associated with increased CVD risk. One such example is the identification of Single Nucleotide Polymorphisms (SNPs) in the 9p21 region, which have been linked to coronary artery disease. Individuals carrying these variants have a higher risk of developing CVD, even in the absence of traditional risk factors. Genetic testing for such markers can be integrated into routine screening to identify high-risk individuals early, allowing for personalized prevention strategies. Polygenic Risk Scores (PRS) are another emerging tool that combines the effects of multiple genetic variants to provide an overall risk estimate for CVD. By assessing the cumulative impact of numerous SNPs, PRS can offer a more comprehensive assessment of an individual's genetic risk, potentially improving the accuracy of early detection efforts. Epigenetics refers to heritable changes in gene expression that do not involve alterations in the DNA sequence. These changes can be influenced by environmental factors such as diet, exercise, and stress, making epigenetic biomarkers particularly relevant for understanding the interplay between genetics and lifestyle in CVD development. DNA methylation is one of the most studied epigenetic modifications in the context of cardiovascular disease. Specific patterns of DNA methylation have been associated with CVD risk and progression. For example, hyper methylation of the gene encoding 5-lipoxygenase has been linked to an increased risk of atherosclerosis, a key contributor to CVD. Detecting such epigenetic changes in blood samples could provide an early warning sign of cardiovascular disease, potentially before significant arterial damage occurs [2,3].

MicroRNAs are another class of epigenetic biomarkers gaining attention in CVD research. These small, non-coding RNAs regulate gene expression and have been implicated in various cardiovascular processes, including inflammation, endothelial function, and myocardial injury. Circulating miRNAs, detectable in blood samples, have shown promise as early indicators of CVD. For example, miR-1, miR-133a, and miR-499 are elevated in patients with acute myocardial infarction, suggesting their potential as biomarkers for early detection of heart attacks. Proteins are the workhorses of the cell, involved in nearly all physiological processes, including those related to cardiovascular health. Several protein-based biomarkers have emerged as potential tools for early CVD detection, offering insights into the underlying biological mechanisms driving disease development. High-sensitivity C-reactive protein is a well-established biomarker of inflammation that has been linked to cardiovascular risk. Elevated levels of hs-CRP are associated with an increased risk of heart attacks and strokes, even in individuals with normal cholesterol levels. As a result, hs-CRP testing is increasingly being used in conjunction with traditional risk factors to improve early detection and risk stratification. Another promising protein-based biomarker is galectin-3, a molecule involved in fibrosis and inflammation. Elevated levels of galectin-3 have been observed in patients with heart failure and are associated with worse outcomes. Measuring galectin-3 levels could help identify individuals at risk for heart failure before clinical symptoms appear, allowing for earlier intervention [4].

Troponins, proteins released during myocardial injury, have long been used as diagnostic markers for acute myocardial infarction. However, recent advancements in high-sensitivity troponin assays have enabled the detection of very low levels of these proteins, even in asymptomatic individuals. This has opened the door to using troponins as a biomarker for subclinical myocardial damage, potentially identifying individuals at risk for future cardiac events. Metabolomics and lipidomics are rapidly evolving fields that study the small molecules and lipids involved in cellular processes. These fields have the potential to uncover novel biomarkers for early CVD detection by providing a snapshot of the metabolic and lipid profiles associated with disease states. For instance, specific lipid profiles have been associated with an increased risk of cardiovascular disease. Elevated levels of certain ceramists, a class of lipids, have been linked to an increased risk of coronary artery disease and heart failure. Measuring these lipid profiles could offer a new avenue for early detection and risk assessment. Similarly, metabolomics studies have identified alterations in amino acid and fatty acid metabolism in individuals at risk for CVD. For example, elevated levels of Branched-Chain Amino Acids (BCAAs) have been associated with insulin resistance and increased CVD risk. By integrating metabolomics and lipidomic data, researchers can develop more precise biomarkers for early CVD detection, potentially identifying at-risk individuals before the onset of traditional risk factors [5].

Conclusion

The discovery of novel biomarkers for early detection of cardiovascular

***Address for Correspondence:** Stefani Karan, Department of Vascular Surgery, Aix Marseille University, Marseille, France; E-mail: skaran@gmail.com*

Received: 03 August, 2024, Manuscript No. jcdd-24-145655; **Editor assigned:** 05 August, 2024, PreQC No. P-145655; **Reviewed:** 17 August, 2024, QC No. Q-145655; **Revised:** 22 August, 2024, Manuscript No. R-145655; **Published:** 29 August, 2024, DOI: 10.37421/2329-9517.2024.12.620

disease represents a significant advancement in preventive cardiology. Genetic markers, epigenetic factors, protein-based indicators, and emerging metabolomics and lipidomic profiles offer new opportunities for identifying individuals at risk for CVD before clinical symptoms appear. While these biomarkers hold great promise, further research is needed to validate their clinical utility and integrate them into routine practice. As our understanding of cardiovascular biology continues to evolve, these novel biomarkers have the potential to revolutionize how we detect, prevent, and manage cardiovascular disease, ultimately improving patient outcomes and reducing the global burden of CVD.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ubeda, Carlos, Luisa Salazar, Viviana Retana and Freddy Santos, et al. "Characterization and experimental measurements of scatter dose at cardiologist's eyes during paediatric interventional cardiology procedures in Costa Rica." *Radiat Prot Dosim* 176 (2017): 450-455.
2. Azizmohammadi, Fariba, Iñaki Navarro Castellanos, Joaquim Miró and Paul Segars, et al. "Generative learning approach for radiation dose reduction in X-ray guided cardiac interventions." *Med Phys* 49 (2022): 4071-4081.
3. Vano, E., C. Ubeda, F. Leyton and P. Miranda. "Radiation dose and image quality for paediatric interventional cardiology." *Phys Med Biol* 53 (2008): 4049.
4. Bor, Dogan, Ozlem Birgul, Umran Onal and Turan Olgar. "Investigation of grid performance using simple image quality tests." *J Med Phys* 41 (2016): 21.
5. Huda, Walter, Anthony M. Sajewicz, Kent M. Ogden and David R. Dance. "Experimental investigation of the dose and image quality characteristics of a digital mammography imaging system." *Med Phys* 30 (2003): 442-448.

How to cite this article: Karan, Stefani. “Novel Biomarkers for Early Detection of Cardiovascular Disease.” *J Cardiovasc Dis Diagn* 12 (2024): 620.